| With gene editing, specialists can remove cells from your body, edit them, and then reintroduce them back into the body to treat a good deal of medical issues. Due to advances in gene-editing, analysts at Markets and Markets say the market could be worth nearly $10.6 billion by 2028 from $5.3 billion in 2023. |
Stansberry Research
Urgent Alert: ‘This Could Be Worth 20 Times More Than Nvidia’
Whitney Tilson has nailed many of the most famous stocks of the past 25 years – including Netflix, Amazon, and Apple. Now he’s pounding the table on a new technology rolling out across America, which early estimates say could create more wealth than AI, the personal computer, and the smartphone combined.
Click here to see how it could become the No. 1 investment of the next decade.
| With growing excitement, keep an eye on cheap gene editing stocks such as: In early December, CRISPR Therapeutics (SYM: CRSP) won Food & Drug Administration approval for its sickle-cell treatment. It also received clearance for its gene-edited therapy for transfusion-dependent beta-thalassemia (TDT). Both of which sent the stock to a high of about $91 by Feb. 2024. Nowadays, we’re waiting on new clinical data from its CAR-T pipeline. Its CTX112, for example, is now in a Phase 1/2 trial for CD19 positive relapsed or refractory B-cell malignancies, with the company expected to post preliminary data this year. Its CTX131, being developed for solid tumors, is also heading into hematologic malignancies this year. |
Investing Trends
Breaking: Microsoft Engineers Give Nod to Next Big AI Player
This one company is vetted by industry giants and it’s trading at under $0.50.
Find out why Microsoft already vetted a company this small…before it hits Wall Street’s radar.
| Company: Intellia Therapeutics (SYM: NTLA) Intellia Therapeutics (SYM: NTLA) could see higher highs. All thanks to its newly released data for hereditary angioedema, or HAE. Just recently, NTLA pushed higher on positive data from a Phase 1 study of NTLA-2002 for hereditary angioedema. In fact, as noted by the company, a single dose of NTLA-2002 led to a 98% mean reduction in the monthly heart attack rate, and a 99% average reduction in moderate to severe attacks. “These unprecedented data strengthen our view that NTLA-2002 could be a groundbreaking treatment for people living with hereditary angioedema,” said Intellia President and Chief Executive Officer John Leonard, M.D. |
Behind the Markets
“Chilling War Games Show US Forces Crushed” – FOX NEWS
After losing to China in repeated war games, U.S. military to spend billions on new “living missile” for armed forces.
Investors stand to reap 35,960% on shares of small defense contractor that makes powerful new weapon.
Get the name of the stock here >>>
